Literature DB >> 12212830

The influence of l-carnitine supplementation on hematocrit and hemoglobin levels in patients with end stage renal failure on CAPD.

Nikolaos Sotirakopoulos1, George Athanasiou, Telemachos Tsitsios, Konstantinos Mavromatidis.   

Abstract

The influence of L-carnitine supplementation on hematocrit (Hct) and hemoglobin (Hb) levels, in patients suffering from end stage renal disease (ESRD) on maintenance hemodialysis, are well known from several studies. The data concerning the serum levels of carnitine, in patients with ESRD on continuous ambulatory peritoneal dialysis (CAPD) are contradictory, but most of them support that they are rather normal. In this study the effect of L-carnitine supplementation on Hct, and Hb levels were investigated in patients suffering from ESRD on CAPD. In the study 12 patients were included (5F, 7M), aged from 39 to 92 years old (median 65.5 years), who were on CAPD for more than 6 months (from 6 to 15 months, mean +/- SD = 8.6 +/- 3.6), with normal serum ferrum and ferritin levels at the beginning of the study. Two grams of L-carnitine/ day per os (Superamin, Vianex Hellas), were administered in all the patients and the serum ferrum levels were tried to be kept stable, by exogenous ferrum administration, during the study period. If the Hct levels were more than 36% per month the erythropoietin (rHuEpo) dose of the patient was decreased monthly at the half dose/week. The changes of Hct, Hb, ferrum and ferritin levels, as well as the Indice de Rigidite (IR) of the erythrocytes were recorded, before and after the first, second and third month of the study period. Finally, the rHuEpo dose/ patient was registered monthly before and during the study. During the observations, Hct (35.4 +/- 3.3 vs. 38.1 +/- 3.4, ANOVA, p < 0.03) and Hb levels (11.0 +/- 1.1 vs. 11.9 +/- 1, ANOVA, p < 0.01), were significantly increased. On the other hand, rHuEpo dose necessity/patient/week was decreased significantly (3,833 +/- 3326 vs. 1,292 +/- 1,712, ANOVA, p < 0.01), in order to succeed the target Hct level. Furthermore, red blood cells IR also appeared to have a significant decrease (16.6 +/- 7.4 vs. 13.0 +/- 3.9, paired t-test, p < 0.03). Finally, the ferrum and ferritin levels were stable during the study period. It was concluded, that in patients on, CAPD the per os L-carnitine supplementation decreased, the red blood cells IR which contributes to the: (a) Increase of Hct and Hb levels and (b) decrease of the patients rHuEpo dose/week.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12212830     DOI: 10.1081/jdi-120006777

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

1.  L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.

Authors:  Michele Malaguarnera; Marco Vacante; Maria Giordano; Massimo Motta; Gaetano Bertino; Manuela Pennisi; Sergio Neri; Mariano Malaguarnera; Giovanni Li Volti; Fabio Galvano
Journal:  World J Gastroenterol       Date:  2011-10-21       Impact factor: 5.742

2.  Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.

Authors:  Shinya Sato; Kei Moriya; Masanori Furukawa; Soichiro Saikawa; Tadashi Namisaki; Mitsuteru Kitade; Hideto Kawaratani; Kosuke Kaji; Hiroaki Takaya; Naotaka Shimozato; Yasuhiko Sawada; Kenichiro Seki; Koh Kitagawa; Takemi Akahane; Akira Mitoro; Yasushi Okura; Junichi Yamao; Hitoshi Yoshiji
Journal:  Clin Mol Hepatol       Date:  2019-02-25

3.  Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Peritoneal Dialysis.

Authors:  Satoshi Shimizu; Hiroyuki Takashima; Ritsukou Tei; Tetsuya Furukawa; Makiyo Okamura; Maki Kitai; Chinami Nagura; Takashi Maruyama; Terumi Higuchi; Masanori Abe
Journal:  Nutrients       Date:  2019-11-04       Impact factor: 5.717

4.  Association between carnitine deficiency and the erythropoietin resistance index in patients undergoing peritoneal dialysis: a cross-sectional observational study.

Authors:  Shohei Kaneko; Keiji Hirai; Junki Morino; Saori Minato; Katsunori Yanai; Yuko Mutsuyoshi; Hiroki Ishii; Momoko Matsuyama; Taisuke Kitano; Mitsutoshi Shindo; Akinori Aomatsu; Haruhisa Miyazawa; Yuichiro Ueda; Kiyonori Ito; Susumu Ookawara; Yoshiyuki Morishita
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

Review 5.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

Review 6.  Current Opinion on Usage of L-Carnitine in End-Stage Renal Disease Patients on Peritoneal Dialysis.

Authors:  Mario Bonomini; Lorenzo Di Liberato; Victor Zammit; Arduino Arduini
Journal:  Molecules       Date:  2019-09-23       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.